Prolonged alendronate treatment prevents the decline in serum TGF-β1 levels and reduces cortical bone strength in long-term estrogen deficiency rat model

Bone

Volumn 52, Issue 1, 2013, Pages 424-432

  Jia, Junjing ^a   Yao, Wei ^a   Amugongo, Sarah ^a   Shahnazari, Mohammad ^a,d   Dai, Weiwei ^a   Lay, Yu An E ^a   Olvera, Diana ^b   Zimmermann, Elizabeth A ^b   Ritchie, Robert O ^b,c   Li, Chin Shang ^e   Alliston, Tamara ^f   Lane, Nancy E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^c University of California Berkeley   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alendronate; Bone quality; Cortical bone; TGF 1

Indexed keywords

ALENDRONIC ACID; ESTROGEN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOMECHANICS; BONE DENSITY; BONE MINERALIZATION; BONE STRENGTH; COMPUTER ASSISTED TOMOGRAPHY; CORTICAL BONE; DRUG EFFECT; ESTROGEN DEFICIENCY; FEMALE; MESENCHYMAL STEM CELL; NONHUMAN; OSTEOCYTE; PERIOSTEUM; RAT; THREE DIMENSIONAL IMAGING; TIBIA; TRABECULAR BONE; VERTEBRA;

ALENDRONATE; ANIMALS; BIOMECHANICS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; ESTROGENS; FEMALE; IMMUNOHISTOCHEMISTRY; MODELS, ANIMAL; POLYMERASE CHAIN REACTION; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84869232218     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.10.017     Document Type: Article

References (76)

1. Fromigue O., Body J.J. Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. J Endocrinol Invest 2002, 25:539-546.
2. Im G.I., Qureshi S.A., Kenney J., Rubash H.E., Shanbhag A.S. Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 2004, 25:4105-4115.
3. Reinholz G.G., Getz B., Pederson L., Sanders E.S., Subramaniam M., Ingle J.N., et al. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 2000, 60:6001-6007.
4. Reszka A.A., Rodan G.A. Mechanism of action of bisphosphonates. Curr Osteoporos Rep 2003, 1:45-52.
5. Balooch G., Yao W., Ager J.W., Balooch M., Nalla R.K., Porter A.E., et al. The aminobisphosphonate risedronate preserves localized mineral and material properties of bone in the presence of glucocorticoids. Arthritis Rheum 2007, 56:3726-3737.
6. Boivin G., Lips P., Ott S.M., Harper K.D., Sarkar S., Pinette K.V., et al. Contribution of raloxifene and calcium and vitamin D3 supplementation to the increase of the degree of mineralization of bone in postmenopausal women. J Clin Endocrinol Metab 2003, 88:4199-4205.
7. Boivin G.Y., Chavassieux P.M., Santora A.C., Yates J., Meunier P.J. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000, 27:687-694.
8. Borah B., Dufresne T.E., Ritman E.L., Jorgensen S.M., Liu S., Chmielewski P.A., et al. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone 2006, 39:345-352.
9. Borah B., Ritman E.L., Dufresne T.E., Jorgensen S.M., Liu S., Sacha J., et al. The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover. Bone 2005, 37:1-9.
10. Follet H., Boivin G., Rumelhart C., Meunier P.J. The degree of mineralization is a determinant of bone strength: a study on human calcanei. Bone 2004, 34:783-789.
11. Yao W., Cheng Z., Koester K.J., Ager J.W., Balooch M., Pham A., et al. The degree of bone mineralization is maintained with single intravenous bisphosphonates in aged estrogen-deficient rats and is a strong predictor of bone strength. Bone 2007, 41:804-812.
12. Zoehrer R., Roschger P., Paschalis E.P., Hofstaetter J.G., Durchschlag E., Fratzl P., et al. Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women. J Bone Miner Res 2006, 21:1106-1112.
13. Plotkin L.I., Aguirre J.I., Kousteni S., Manolagas S.C., Bellido T. Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem 2005, 280:7317-7325.
14. Bivi N., Bereszczak J.Z., Romanello M., Zeef L.A., Delneri D., Quadrifoglio F., et al. Transcriptome and proteome analysis of osteocytes treated with nitrogen-containing bisphosphonates. J Proteome Res 2009, 8:1131-1142.
15. Bivi N., Picotti P., Muller L.N., Romanello M., Moro L., Quadrifoglio F., et al. Shotgun proteomics analysis reveals new unsuspected molecular effectors of nitrogen-containing bisphosphonates in osteocytes. J Proteomics 2011, 74:1113-1122.
16. Plotkin L.I., Lezcano V., Thostenson J., Weinstein R.S., Manolagas S.C., Bellido T. Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res 2008, 23:1712-1721.
17. Plotkin L.I., Manolagas S.C., Bellido T. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone 2006, 39:443-452.
18. Oursler M.J. Osteoclast synthesis and secretion and activation of latent transforming growth factor beta. J Bone Miner Res 1994, 9:443-452.
19. Tang Y., Wu X., Lei W., Pang L., Wan C., Shi Z., et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med 2009, 15:757-765.
20. Atfi A., Baron R. PTH battles TGF-beta in bone. Nat Cell Biol 2010, 12:205-207.
21. Alliston T., Piek E., Derynck R. TGF-β family signaling in skeletal development, maintenance, and disease. TGF-β Family: Cold Spring Harbor Monogragh Archive 2008, 667-724.
22. Davis J., Tucci M., Franklin L., Russell G., Benghuzzi H. The effects of growth factors on the production of osteopontin and osteocalcin. Biomed Sci Instrum 2006, 42:31-36.
23. Filvaroff E., Erlebacher A., Ye J., Gitelman S.E., Lotz J., Heillman M., et al. Inhibition of TGF-beta receptor signaling in osteoblasts leads to decreased bone remodeling and increased trabecular bone mass. Development 1999, 126:4267-4279.
24. Aerssens J., Van Audekercke R., Geusens P., Schot L.P., Osman A.A., Dequeker J. Mechanical properties, bone mineral content, and bone composition (collagen, osteocalcin, IGF-I) of the rat femur: influence of ovariectomy and nandrolone decanoate (anabolic steroid) treatment. Calcif Tissue Int 1993, 53:269-277.
25. Oursler M.J., Cortese C., Keeting P., Anderson M.A., Bonde S.K., Riggs B.L., et al. Modulation of transforming growth factor-beta production in normal human osteoblast-like cells by 17 beta-estradiol and parathyroid hormone. Endocrinology 1991, 129:3313-3320.
26. Oursler M.J., Riggs B.L., Spelsberg T.C. Glucocorticoid-induced activation of latent transforming growth factor-beta by normal human osteoblast-like cells. Endocrinology 1993, 133:2187-2196.
27. Bailey Dubose K., Zayzafoon M., Murphy-Ullrich J.E. Thrombospondin-1 inhibits osteogenic differentiation of human mesenchymal stem cells through latent TGF-beta activation. Biochem Biophys Res Commun 2012, 422(3):488-493.
28. Erlebacher A., Filvaroff E.H., Ye J.Q., Derynck R. Osteoblastic responses to TGF-beta during bone remodeling. Mol Biol Cell 1998, 9:1903-1918.
29. Mundy G.R., Bonewald L.F. Role of TGF beta in bone remodeling. Ann N Y Acad Sci 1990, 593:91-97.
30. Balooch G., Balooch M., Nalla R.K., Schilling S., Filvaroff E.H., Marshall G.W., et al. TGF-beta regulates the mechanical properties and composition of bone matrix. Proc Natl Acad Sci U S A 2005, 102:18813-18818.
31. Alliston T. TGF-beta regulation of osteoblast differentiation and bone matrix properties. J Musculoskelet Neuronal Interact 2006, 6:349-350.
32. Mohammad K.S., Chen C.G., Balooch G., Stebbins E., McKenna C.R., Davis H., et al. Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS One 2009, 4:e5275.
33. Boskey A.L., Spevak L., Paschalis E., Doty S.B., McKee M.D. Osteopontin deficiency increases mineral content and mineral crystallinity in mouse bone. Calcif Tissue Int 2002, 71:145-154.
34. Kinney J.H., Haupt D.L., Balooch M., Ladd A.J., Ryaby J.T., Lane N.E. Three-dimensional morphometry of the L6 vertebra in the ovariectomized rat model of osteoporosis: biomechanical implications. J Bone Miner Res 2000, 15:1981-1991.
35. Lane N.E., Kumer J., Yao W., Breunig T., Wronski T., Modin G., et al. Basic fibroblast growth factor forms new trabeculae that physically connect with pre-existing trabeculae, and this new bone is maintained with an anti-resorptive agent and enhanced with an anabolic agent in an osteopenic rat model. Osteoporos Int 2003, 14:374-382.
36. Lane N.E., Yao W., Balooch M., Nalla R.K., Balooch G., Habelitz S., et al. Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J Bone Miner Res 2006, 21:466-476.
37. Dallas S.L., Park-Snyder S., Miyazono K., Twardzik D., Mundy G.R., Bonewald L.F. Characterization and autoregulation of latent transforming growth factor beta (TGF beta) complexes in osteoblast-like cell lines. Production of a latent complex lacking the latent TGF beta-binding protein. J Biol Chem 1994, 269:6815-6821.
38. Yoshitake H., Rittling S.R., Denhardt D.T., Noda M. Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc Natl Acad Sci U S A 1999, 96:8156-8160.
39. Yao W., Balooch G., Balooch M., Jiang Y., Nalla R.K., Kinney J., et al. Sequential treatment of ovariectomized mice with bFGF and risedronate restored trabecular bone microarchitecture and mineralization. Bone 2006, 39(3):460-469.
40. Yao W., Hadi T., Jiang Y., Lotz J., Wronski T.J., Lane N.E. Basic fibroblast growth factor improves trabecular bone connectivity and bone strength in the lumbar vertebral body of osteopenic rats. Osteoporos Int 2005, 16:1939-1947.
41. Shahnazari M., Yao W., Dai W., Wang B., Ionova-Martin S.S., Ritchie R.O., et al. Higher doses of bisphosphonates further improve bone mass, architecture, and strength but not the tissue material properties in aged rats. Bone 2010, 46:1267-1274.
42. Guan M., Yao W., Liu R., Lam K.S., Nolta J., Jia J., et al. Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass. Nat Med 2012, 18:456-462.
43. Rittling S.R., Matsumoto H.N., McKee M.D., Nanci A., An X.R., Novick K.E., et al. Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J Bone Miner Res 1998, 13:1101-1111.
44. Estai M.A., Suhaimi F., Das S., Shuid A.N., Mohamed Z., Soelaiman I.N. Expression of TGF-beta1 in the blood during fracture repair in an estrogen-deficient rat model. Clinics (Sao Paulo) 2011, 66:2113-2119.
45. Xia X., Kar R., Gluhak-Heinrich J., Yao W., Lane N.E., Bonewald L.F., et al. Glucocorticoid induced autophagy in osteocytes. J Bone Miner Res 2010, 25(11):2479-2488.
46. Kato Y., Windle J.J., Koop B.A., Mundy G.R., Bonewald L.F. Establishment of an osteocyte-like cell line, MLO-Y4. J Bone Miner Res 1997, 12:2014-2023.
47. Donnelly E., Meredith D.S., Nguyen J.T., Gladnick B.P., Rebolledo B.J., Shaffer A.D., et al. Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures. J Bone Miner Res 1997, 12(12):2014-2023.
48. Chen Q., Sivakumar P., Barley C., Peters D.M., Gomes R.R., Farach-Carson M.C., et al. Potential role for heparan sulfate proteoglycans in regulation of transforming growth factor-beta (TGF-beta) by modulating assembly of latent TGF-beta-binding protein-1. J Biol Chem 2007, 282:26418-26430.
49. Ashcroft G.S., Dodsworth J., van Boxtel E., Tarnuzzer R.W., Horan M.A., Schultz G.S., et al. Estrogen accelerates cutaneous wound healing associated with an increase in TGF-beta1 levels. Nat Med 1997, 3:1209-1215.
50. Zimmermann G., Henle P., Kusswetter M., Moghaddam A., Wentzensen A., Richter W., et al. TGF-beta1 as a marker of delayed fracture healing. Bone 2005, 36:779-785.
51. Centrella M., Ji C., McCarthy T.L. Control of TGF-beta receptor expression in bone. Front Biosci 1998, 3:d113-d124.
52. Chang J.L., Brauer D.S., Johnson J., Chen C.G., Akil O., Balooch G., et al. Tissue-specific calibration of extracellular matrix material properties by transforming growth factor-beta and Runx2 in bone is required for hearing. EMBO Rep 2010, 11:765-771.
53. Warde N. Bone: effects of bisphosphonates on bone quality components and fracture risk. Nat Rev Rheumatol 2012, 8:3.
54. Bismar H., Kloppinger T., Schuster E.M., Balbach S., Diel I., Ziegler R., et al. Transforming growth factor beta (TGF-beta) levels in the conditioned media of human bone cells: relationship to donor age, bone volume, and concentration of TGF-beta in human bone matrix in vivo. Bone 1999, 24:565-569.
55. Khosla S., Bilezikian J.P., Dempster D.W., Lewiecki E.M., Miller P.D., Neer R.M., et al. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab 2012, 97(7):2272-2282. [Epub 2012 Apr 20].
56. Fox S.W., Evans K.E., Lovibond A.C. Transforming growth factor-beta enables NFATc1 expression during osteoclastogenesis. Biochem Biophys Res Commun 2008, 366:123-128.
57. Fox S.W., Lovibond A.C. Current insights into the role of transforming growth factor-beta in bone resorption. Mol Cell Endocrinol 2005, 243:19-26.
58. Lieb E., Vogel T., Milz S., Dauner M., Schulz M.B. Effects of transforming growth factor beta1 on bonelike tissue formation in three-dimensional cell culture. II: osteoblastic differentiation. Tissue Eng 2004, 10:1414-1425.
59. Breen E.C., Ignotz R.A., McCabe L., Stein J.L., Stein G.S., Lian J.B. TGF beta alters growth and differentiation related gene expression in proliferating osteoblasts in vitro, preventing development of the mature bone phenotype. J Cell Physiol 1994, 160:323-335.
60. Borton A.J., Frederick J.P., Datto M.B., Wang X.F., Weinstein R.S. The loss of Smad3 results in a lower rate of bone formation and osteopenia through dysregulation of osteoblast differentiation and apoptosis. J Bone Miner Res 2001, 16:1754-1764.
61. Geiser A.G., Zeng Q.Q., Sato M., Helvering L.M., Hirano T., Turner C.H. Decreased bone mass and bone elasticity in mice lacking the transforming growth factor-beta1 gene. Bone 1998, 23:87-93.
62. Alliston T., Choy L., Ducy P., Karsenty G., Derynck R. TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. EMBO J 2001, 20:2254-2272.
63. Dallas S.L., Rosser J.L., Mundy G.R., Bonewald L.F. Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J Biol Chem 2002, 277:21352-21360.
64. Kang J.S., Alliston T., Delston R., Derynck R. Repression of Runx2 function by TGF-beta through recruitment of class II histone deacetylases by Smad3. EMBO J 2005, 24:2543-2555.
65. Maeda S., Hayashi M., Komiya S., Imamura T., Miyazono K. Endogenous TGF-beta signaling suppresses maturation of osteoblastic mesenchymal cells. EMBO J 2004, 23:552-563.
66. Gao Y., Qian W.P., Dark K., Toraldo G., Lin A.S., Guldberg R.E., et al. Estrogen prevents bone loss through transforming growth factor beta signaling in T cells. Proc Natl Acad Sci U S A 2004, 101:16618-16623.
67. Hughes D.E., Dai A., Tiffee J.C., Li H.H., Mundy G.R., Boyce B.F. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med 1996, 2:1132-1136.
68. Pan B., To L.B., Farrugia A.N., Findlay D.M., Green J., Gronthos S., et al. The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro. Bone 2004, 34:112-123.
69. Durchschlag E., Paschalis E.P., Zoehrer R., Roschger P., Fratzl P., Recker R., et al. Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate. J Bone Miner Res 2006, 21:1581-1590.
70. Roschger P., Rinnerthaler S., Yates J., Rodan G.A., Fratzl P., Klaushofer K. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 2001, 29:185-191.
71. Bauss F., Dempster D.W. Effects of ibandronate on bone quality: preclinical studies. Bone 2007, 40:265-273.
72. Lane N.E., Yao W., Kinney J.H., Modin G., Balooch M., Wronski T.J. Both hPTH(1-34) and bFGF increase trabecular bone mass in osteopenic rats but they have different effects on trabecular bone architecture. J Bone Miner Res 2003, 18:2105-2115.
73. Black D.M., Schwartz A.V., Ensrud K.E., Cauley J.A., Levis S., Quandt S.A., et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006, 296:2927-2938.
74. Turner C.H., Burr D.B. Basic biomechanical measurements of bone: a tutorial. Bone 1993, 14:595-608.
75. Allen M.R., Burr D.B. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res 2007, 22:1759-1765.
76. Bala Y., Depalle B., Farlay D., Douillard T., Meille S., Follet H., et al. Bone micromechanical properties are compromised during long-term alendronate therapy independently of mineralization. J Bone Miner Res 2012, 27:825-834.